170919-Transgene-FPI-Announcement_US
Category: Press release
First half-year 2017 in line with our objectives: All clinical programs progressing and new collaboration agreements signed
20170913 EN – CP Resultats financiers final
Transgene Receives FDA IND Approval to Begin a Clinical Trial with TG4010 + Nivolumab + Chemotherapy in the First-Line Treatment of Lung Cancer (NSCLC)
Transgene and Institut Bergonié Present a Poster on the METROmaJX Trial (Oncolytic Virus Pexa-Vec + Metronomic Cyclophosphamide) at ESMO 2017 Congress
20170907-ESMO-Metromajx-poster-EN
Transgene Announces Upcoming Investor Meetings
TNG-PR-financial-agenda-H217-EN
First Patient Dosed in a Phase 1/2 Trial of Pexa-Vec + Opdivo® for the First-Line Treatment of Advanced Liver Cancer
PR Pexa-Vec nivo EN
Transgene Announces Cancer Research Publication Confirming the Potential of its Next Generation Armed Engineered Oncolytic Virus
20170724 PR CancerResearch
Servier and Transgene have become partners to apply viral vectorization technology to the engineering of allogenic CAR-T.
20170629 Servier Transgene EN
Transgene Hosts Immuno-Oncology R&D Day Focused on Modulating the Tumor Micro-Environment in Paris
20170622 CP RD Day EN
Combined General Meeting of June 8, 2017
20170608 TG AGM June 2017 EN